Skip to main content

Fresenius Medical Care AG

corporate_fare Company Profile

Fresenius Medical Care AG

FMS·NYSE·Industrial Applications And Services·CIK 0001333141

The company is engaged in a strategic review and optimization of its business portfolio. For the year ended December 31, 2025, the company focused on exiting unsustainable markets and divesting non-core businesses, as well as ceasing certain research and development programs. This optimization included completed divestitures in Brazil, Malaysia, and Kazakhstan, along with select assets of its wholly owned Spectra Laboratories. Impairment losses were primarily related to right-of-use assets. On June 17, 2025, the company launched its FME Reignite strategy, which includes increased profitability aspirations for 2030 and a new capital allocation framework. This strategy also expanded the transformation of its operating structure into a simplified, more centralized approach, aiming for cost savings. This program, originally named FME25 Program, was extended by two years and renamed the FME25+ Program. The company continues to target sustainable savings, including operational efficiencies, under the FME25+ Program. The FME25 Program introduced two operating segments: Care Enablement and Care Delivery. Care Enablement consolidates the company's previously decentralized healthcare products business, encompassing research and development, manufacturing, supply chain, commercial operations, and supporting functions like regulatory and quality management, under a global MedTech umbrella. Care Delivery combines the company's global healthcare services businesses. Under FME Reignite, these two operating segments were further expanded to include Value-Based Care.

Fresenius Medical Care AG (NYSE:FMS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 19 items for FMS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for FMS spans SCHEDULE 13D/A, 6-K, 20-F.

Recent high-impact activity:

  • Fresenius SE Sells 13.4M FMC Shares at EUR 39.00, Cutting Stake to 20.9%
  • Fresenius Medical Care Q3 Operating Income Down 19%, FY2026 Outlook Narrowed
  • Fresenius Medical Care Names Shervin Korangy as New CEO
  • FDA Warning Letter Hits Fresenius Kabi's Illinois Facility
  • Fresenius Medical Care to Exit China PD Business, Book €110M Q3 Charge

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
€19.63B EUR
Net Income
€1.19B EUR
Diluted EPS
€3.36 EUR
Op. Cash Flow
€2.68B EUR
Gross Profit
€5.03B EUR
Operating Income
€1.83B EUR
Cash & Equivalents
€929.69M EUR
Total Debt
€7.29B EUR
Debt / Equity
0.51×
Net Margin
6.1%
Shares Outstanding
293.41M sh
Source: 20-F · filed 2026-02-24 · accession 0001104659-26-019005

Short Interest & Short Volume

2.21 days to cover

FINRA reported short interest of 3,008,522 shares in FMS as of the October 30, 2026 settlement, a 24.0% decrease from the prior period — about 2.2 days to cover at its recent average daily volume. On November 20, 2026, 50.2% of FMS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,008,522 shares as of October 30, 2026
Change vs prior period▼ 24.0%
Days to cover2.21 at avg daily volume of 1,362,264
Daily short volume (FINRA facilities)50.2% of 465,744 shares on November 20, 2026
5-day average short volume55.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

FMS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with F →
$20.44
52-week range · as of 2026-11-13 $20.02 – $26.42
Market cap
$10.95B
Volume
1.3M (0.8× avg)
3-mo avg 1.6M
Live data · 2026-11-21 10:31 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed FMS - Latest Insights

FMS
Nov 13, 2026, 3:26 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $22.06
Real-time Price: $20.44 info
Change: -$1.62 (-7%) info
Market Cap: $10.954B info
FMS
Nov 03, 2026, 8:04 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $23.02
Real-time Price: $20.44 info
Change: -$2.58 (-11%) info
Market Cap: $10.954B info
FMS
Oct 07, 2026, 12:03 PM EDT
Source: Seeking Alpha
Importance Score:
7
Updated Oct 7, 2:21 PM ET — Korangy's appointment is effective October 12, 2026; he resigned from the Supervisory Board, and Ann Custin was identified as his successor.
Price at Filing: $20.89
Real-time Price: $20.44 info
Change: -$0.450 (-2%) info
Market Cap: $10.954B info
FMS
Sep 29, 2026, 11:01 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $22.12
Real-time Price: $20.44 info
Change: -$1.67 (-8%) info
Market Cap: $10.954B info
FMS
Sep 25, 2026, 7:54 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $22.42
Real-time Price: $20.44 info
Change: -$1.98 (-9%) info
Market Cap: $10.954B info
FMS
Aug 27, 2026, 8:14 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $23.27
Real-time Price: $20.44 info
Change: -$2.83 (-12%) info
Market Cap: $10.954B info
FMS
Aug 24, 2026, 4:09 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.53
Real-time Price: $20.44 info
Change: -$3.09 (-13%) info
Market Cap: $10.954B info
FMS
Aug 04, 2026, 7:59 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $24.10
Real-time Price: $20.44 info
Change: -$3.66 (-15%) info
Market Cap: $10.954B info
FMS
Aug 03, 2026, 2:28 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $25.36
Real-time Price: $20.44 info
Change: -$4.92 (-19%) info
Market Cap: $10.954B info
FMS
Aug 03, 2026, 2:26 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $25.38
Real-time Price: $20.44 info
Change: -$4.94 (-19%) info
Market Cap: $10.954B info
FMS
Jul 29, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $24.51
Real-time Price: $20.44 info
Change: -$4.07 (-17%) info
Market Cap: $10.954B info
FMS
May 28, 2026, 9:12 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $21.55
Real-time Price: $20.44 info
Change: -$1.11 (-5%) info
Market Cap: $10.954B info
FMS
May 26, 2026, 9:59 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $21.65
Real-time Price: $20.44 info
Change: -$1.21 (-6%) info
Market Cap: $10.954B info
FMS
May 05, 2026, 10:43 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $20.33
Real-time Price: $20.44 info
Change: +$0.110 (+0.54%) info
Market Cap: $10.954B info
FMS
May 05, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $21.66
Real-time Price: $20.44 info
Change: -$1.22 (-6%) info
Market Cap: $10.954B info
FMS
Apr 14, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $23.43
Real-time Price: $20.44 info
Change: -$2.99 (-13%) info
Market Cap: $10.954B info
FMS
Feb 24, 2026, 12:41 PM EST
Filing Type: 20-F
Importance Score:
9
Price at Filing: $22.75
Real-time Price: $20.44 info
Change: -$2.30 (-10%) info
Market Cap: $10.954B info
FMS
Feb 24, 2026, 6:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $22.91
Real-time Price: $20.44 info
Change: -$2.47 (-11%) info
Market Cap: $10.954B info
FMS
Jan 12, 2026, 6:02 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $23.50
Real-time Price: $20.44 info
Change: -$3.06 (-13%) info
Market Cap: $10.954B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets